Cite
Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF).
MLA
Bonfield, Tracey L., et al. “Human Mesenchymal Stem Cell (HMSC) Donor Potency Selection for the ‘First in Cystic Fibrosis’ Phase I Clinical Trial (CEASE-CF).” Pharmaceuticals (14248247), vol. 16, no. 2, Feb. 2023, p. 220. EBSCOhost, https://doi.org/10.3390/ph16020220.
APA
Bonfield, T. L., Sutton, M. T., Fletcher, D. R., Reese-Koc, J., Roesch, E. A., Lazarus, H. M., Chmiel, J. F., & Caplan, A. I. (2023). Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF). Pharmaceuticals (14248247), 16(2), 220. https://doi.org/10.3390/ph16020220
Chicago
Bonfield, Tracey L., Morgan T. Sutton, David R. Fletcher, Jane Reese-Koc, Erica A. Roesch, Hillard M. Lazarus, James F. Chmiel, and Arnold I. Caplan. 2023. “Human Mesenchymal Stem Cell (HMSC) Donor Potency Selection for the ‘First in Cystic Fibrosis’ Phase I Clinical Trial (CEASE-CF).” Pharmaceuticals (14248247) 16 (2): 220. doi:10.3390/ph16020220.